



US00D800912S

(12) **United States Design Patent** (10) **Patent No.:** **US D800,912 S**
Uzri et al. (45) **Date of Patent:** **** Oct. 24, 2017**

(54) **POINT-OF-CARE DIAGNOSTIC DEVICE**

(71) Applicant: **Abreos Biosciences, Inc.**, La Jolla, CA (US)

(72) Inventors: **Dina Uzri**, San Diego, CA (US);
Benedict L. Zin, San Diego, CA (US);
Bradley Todd Messmer, San Diego, CA (US); **Inhoe Kim**, San Diego, CA (US); **Gad Shaanan**, San Diego, CA (US); **Jessie-Farah Fecteau**, Escondido, CA (US)

(73) Assignee: **ABREOS BIOSCIENCES, INC.**, San Diego, CA (US)

(**) Term: **15 Years**

(21) Appl. No.: **29/568,417**

(22) Filed: **Jun. 17, 2016**

(51) **LOC (10) Cl.** **24-01**

(52) **U.S. Cl.**
USPC **D24/216**

(58) **Field of Classification Search**

USPC D24/216, 107, 169, 186, 231, 232, 233;
D10/81

CPC G01N 2035/00306; G01N 2035/00326;
G01N 2035/00336; G01N 33/53; G01N
33/5302; G01N 33/569; C12Q 1/686;
B01L 7/52

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,281,395 A	1/1994	Markart et al.
5,413,764 A	5/1995	Haar
5,567,594 A	10/1996	Calenoff
5,885,577 A	3/1999	Alvarez
6,146,589 A	11/2000	Chandler

6,210,901 B1	4/2001	Seidel et al.
7,074,888 B1	7/2006	Miller et al.
8,193,002 B2	6/2012	Guo et al.

(Continued)

FOREIGN PATENT DOCUMENTS

WO	WO-2007022557 A1	3/2007
WO	WO-2009121024 A2	10/2009

(Continued)

OTHER PUBLICATIONS

Colman et al. Effects of amino acid sequence changes on antibody-antigen interactions. *Research in Immunology* 145(1):33-36 (1994).

(Continued)

Primary Examiner — Wan Laymon

Assistant Examiner — Mark Booker

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **CLAIM**



The ornamental design for a point-of-care diagnostic device, as shown and described.

DESCRIPTION

FIG. 1 is a top perspective view of the point-of-care diagnostic device, as seen from the top, front, and side; FIG. 2 is a top plan view thereof; FIG. 3 is a front elevation view thereof; FIG. 4 is a right side elevation view thereof; FIG. 5 is a left side elevation view thereof; FIG. 6 is a rear elevation view thereof; FIG. 7 is a bottom plan view thereof; and, FIG. 8 is a top perspective view of alternative embodiment of the point-of-care diagnostic device, showing the door slid in the open position.

The broken line depiction of a point-of-care device is included for the purpose of illustrating environmental structure and forms no part of the claimed design.

1 Claim, 5 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

8,507,216	B2	8/2013	Kuroda et al.
9,250,233	B2	2/2016	Kipps et al.
D774,205	S *	12/2016	Grace D24/169
2003/0068664	A1	4/2003	Albitar et al.
2005/0084491	A1	4/2005	Shealy et al.
2005/0191620	A1	9/2005	McDevitt et al.
2005/0208587	A1	9/2005	Cardoso et al.
2005/0272106	A1	12/2005	Moore et al.
2006/0008920	A1	1/2006	Wong et al.
2006/0068501	A1	3/2006	Li et al.
2006/0286379	A1	12/2006	Gao
2010/0330585	A1	12/2010	Kabri et al.
2011/0117636	A1	5/2011	Bae et al.
2011/0136155	A1	6/2011	Mehra et al.
2011/0320130	A1	12/2011	Valdes et al.
2012/0220049	A1	8/2012	Bunce et al.
2012/0225423	A1	9/2012	Schwoebel et al.
2013/0040401	A1	2/2013	Zin et al.
2013/0085349	A1	4/2013	Shaanan et al.
2013/0130404	A1	5/2013	Mehra et al.
2013/0143246	A1	6/2013	Nelson et al.
2015/0293086	A1	10/2015	Messmer et al.
2015/0301031	A1	10/2015	Zin et al.
2016/0146829	A1	5/2016	Kipps et al.

FOREIGN PATENT DOCUMENTS

WO	WO-2012023053	A2	2/2012
WO	WO-2015160834	A1	10/2015
WO	WO-2016123105	A1	8/2016

OTHER PUBLICATIONS

Dalakas et al. Effect of Alemtuzumab (Campath 1H) in patients with inclusion-body myositis. *Brain* 132:1536-1544 (2009).

Harlow et al. *Antibodies: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 23-26 (1988).

Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. *Mol Immunol* 28(11):1171-1181 (1991).

U.S. Appl. No. 14/686,578 Office Action dated Oct. 14, 2016.

U.S. Appl. No. 14/981,715 Office Action dated Jul. 12, 2016.

McDade et al. What a Drop Can Do: Dried Blood Spots As a Minimally Invasive Method for Integrating Biomarkers into Population Based Research. *Demography* 44(4):899-925 (2007).

PCT/US2015/025796 International Preliminary Report on Patentability dated Oct. 27, 2016.

U.S. Serial No. 14/981,715 Office Action dated Jan. 19, 2017.

U.S. Serial No. 15/185,549 Office Action dated Jan. 6, 2017.

Adams et al. Monoclonal antibody therapy of cancer. *Nat Biotechnol.* 23:1147-1157 (2005).

Barenholz et al. A peptide mimetic of the mycobacterial mannosylated lipoarabinomannan: characterization and potential applications. *J Med Microbiol* 56(pt 5):579-586 (2007).

Barnett et al. In-Field Implementation of a Recombinant Factor C Assay for the Detection of Lipopolysaccharide as a Biomarker of Extant Life within Glacial Environments. *Biosensors (Basel)* 2(1):83-100 (2012).

Bazin et al. Rapid visual tests: fast and reliable detection of ochratoxin A. *Toxins (Basel)* 2(9):2230-2241 (2010).

Beum et al. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. *J Immunol Methods* 289(1-2):97-109 (2004).

Blasco et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. *J Immun Methods* 325(1-2):127-139 (2007).

Breidenbach et al. Substrate recognition strategy for botulinum neurotoxin serotype A. *Nature* 432(7019):925-929 (2004).

Brissette et al. Identification of cancer targets and therapeutics using phage display. *Curr Opin Drug Discov Devel* 9:363-369 (2006).

Carpino et al. 9-Fluorenylmethoxycarbonyl amino-protecting group. *J Org Chem* 37(22):3404-3409 (1972).

Co-pending U.S. Appl. No. 15/185,549, filed Jun. 17, 2016.

Co-pending U.S. Appl. No. 29/568,418, filed Jun. 17, 2016.

Degardin et al. Understanding and fighting the medicine counterfeit market. *J Pharm Biomed Anal* 87:167-175 (2013).

Delano et al. Convergent solutions to binding at a protein-protein interface. *Science* 287(5456):1279-1283 (2000).

Ding et al. Endotoxin detection—from limulus amebocyte lysate to recombinant factor C. *Subcell Biochem* 53:187-208 (2010).

FDA—definition of biological product. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm> (Jul. 2015).

Feltrup et al. Development of a fluorescence internal quenching correction factor to correct botulinum neurotoxin type a endopeptidase kinetics using SNAPtide. *Anal Chem* 84(24):10549-10553 (2012).

Fernandez-Salas et al. Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay. *PLoS One* 7(11):e49516 (2012).

Golden et al. Extended result reading window in lateral flow tests detecting exposure to *Onchocerca volvulus*: a new technology to improve epidemiological surveillance tools. *PLoS One* 8(7):e69231 (2013).

Hale et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. *Blood* 104(4):948-955 (2004).

Hale. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. *Immunotechnology* 1(3-4):175-187 (1995).

Jiang et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2 *J Biol Chem* 280(6):4656-4662 (2004).

Jilani et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. *Leuk Res* 28(12):1255-1262 (2004).

Joiner et al. Comparison of Endotoxin Testing Methods for Pharmaceutical Products. *Int J Pharm Compd* 6:408-409 (2002).

Jones et al. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. *J Immunol Meth* 329(1-2):92-101 (2008).

Kosik et al. Studies of enzymatic cleavage of cellulose using polysaccharide analysis by carbohydrate gel electrophoresis (PACE). *Methods Enzymol* 510:51-67 (2012).

Laderman et al. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. *Clin Vaccine Immunol.* 15(1):159-163 (2007).

Lee et al. Performance improvement of the one-dot lateral flow immunoassay for aflatoxin B1 by using a smartphone-based reading system. *Sensors (Basel)* 13(4):5109-5116 (2013).

Lonza Limulus Amebocyte Lysate (LAL) QCL-1000. Available from: <http://bio.lonza.com/uploads/txmwxmarketingmaterial/LonzaManualsProductInstructionsCL-1000ProductInsert.pdf> (2007).

Maloney et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood* 90(6):2188-2195 (1997).

Manshouri et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. *Blood* 101(7):2507-2513 (2002).

Merrifield. Solid Phase Peptide Synthesis I. *J Am Chem Soc* 85:2149-2154 (1963).

Messmer et al. Specific blocking to improve biopanning in biological samples such as serum and hybridoma supernatants. *Biotechniques* 30(4):798-802 (2001).

(56)

References Cited

OTHER PUBLICATIONS

Messmer et al. Two human neonatal IgM antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition. *J Immunol* 162(4):2184-2192 (1999).

Montagna et al. A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application. *Int J Immunopathol Pharmacol* 20(2):363-371 (2007).

Mulvaney et al. Incorporating fluorescent dyes and quantum dots into magnetic microbeads for immunoassays. *Biotechniques* 36(4):602-609 (2004).

Nakamura et al. Lipopolysaccharide-sensitive serine-protease zymogen (factor C) found in *Limulus* hemocytes. Isolation and characterization. *Eur J Biochem* 154:511-521 (1986).

Nakano et al. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. *J Immunol Methods* 293:183-189 (2004).

Ouimet et al. Comparison of Fluorogenic Peptide Substrates PL50, SNAPtide, and BoTest A/E for BoNT/A Detection and Quantification: Exosite Binding Confers High-Assay Sensitivity. *Journal of Biomolecular Screening* 18(6):726-735 (2013).

PCT/US2009/038674 International Preliminary Report on Patentability dated Sep. 28, 2010.

PCT/US2009/038674 International Search Report and Written Opinion dated Dec. 24, 2009.

PCT/US2015/025796 International Search Report and Written Opinion dated Aug. 21, 2015.

PCT/US2016/14924 International Search Report and Written Opinion dated Apr. 8, 2016.

Perosa et al. Identification of an antigenic and immunogenic motif expressed by two 7-merrituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. *J Immunol* 179(11):7967-7974 (2007).

Pierce® LAL Chromogenic Endotoxin Quantitation Kit. Available from: <https://www.piercenet.com/instructions/2162445.pdf> (2013).

Poras et al. Detection and Quantification of Botulinum Neurotoxin Type A by a Novel Rapid In Vitro Fluorimetric Assay. *Applied and Environmental Microbiology* 75(13):4382-4390 (2009).

Rebello et al. Pharmacokinetics of CAMPATH-1H: assay development and validation. *J Immunol Methods* 260(1-2):285-302 (2002).

Rohr et al. Immunoassay employing surface-enhanced Raman spectroscopy. *Anal Biochem* 182(2):388-398 (1989).

Sanchez et al. A general process for the development of peptide-based immunoassays for monoclonal antibodies. *Cancer Chemother Pharmacol* 66(5):919-925 (2010).

Shin et al. Combinatorial solid phase peptide synthesis and bioassays. *J Biochem Mol Biol* 38(5):517-525 (2005).

Sosnick et al. Distances between the antigen-binding sites of three murine antibody subclasses measured using neutron and X-ray scattering. *Biochemistry* 31:1779-1786 (1992).

Tan et al. Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors. *Clin Cancer Res* 12(21):6517-6522 (2006).

Tian et al. Antigen peptide-based immunosensors for rapid detection of antibodies and antigens. *Anal Chem* 81(13):5218-5225 (2009).

Titov et al. Development and optimization of immunoassays for the detection of botulinum toxins. *Prikl Biokhim Mikrobiol* 48(2):249-256 (2012).

Tokunaga et al. Further studies on lipopolysaccharide-sensitive serine protease zymogen (factor C): its isolation from *Limulus polyphemus* hemocytes and identification as an intracellular zymogen activated by alpha-chymotrypsin, not by trypsin. *J Biochem* 109:150-157 (1991).

U.S. Serial No. 12/934,624 Office Action dated Aug. 22, 2014.

U.S. Serial No. 12/934,624 Office Action dated Jan. 8, 2014.

U.S. Serial No. 12/934,624 Office Action dated Mar. 27, 2015.

Wang et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. *Ophthalmology* 120(2):355-361 (2013).

Williams et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. *J Immunol* 177:7435-7443 (2006).

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8